460 — Sihuan Pharmaceutical Holdings Balance Sheet
0.000.00%
- HK$6.39bn
- HK$3.91bn
- CNY1.90bn
- 20
- 33
- 71
- 35
Annual balance sheet for Sihuan Pharmaceutical Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 4,937 | 5,792 | 4,792 | 4,368 | 3,777 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 821 | 1,094 | 978 | 1,045 | 1,424 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 6,404 | 7,741 | 6,550 | 6,204 | 5,718 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,841 | 4,093 | 2,998 | 2,842 | 2,635 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 13,044 | 14,496 | 12,141 | 11,535 | 10,532 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,443 | 2,502 | 2,533 | 4,107 | 3,310 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 3,854 | 6,211 | 7,404 | 7,103 | 6,159 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | 9,190 | 8,284 | 4,737 | 4,432 | 4,372 |
Total Liabilities & Shareholders' Equity | 13,044 | 14,496 | 12,141 | 11,535 | 10,532 |
Total Common Shares Outstanding |